NeuroVive: Interim Report 1 Jan. 2013 till 30 Jun. 2013
Milestones achieved consolidate positioning in mitochondrial medicine Six months (1 Jan. 2013 – 30 Jun. 2013) · Net revenues were SEK 5,335,000 (0) and other operating income was SEK 863,000 (319,000). · Loss before tax was SEK -6,206,000 (-6,871,000). · Earnings per share* were SEK -0.39 (-0.41). · Diluted earnings per share** were SEK -0.39 (-0.41). Second quarter (1 Apr. 2013 – 30 Jun. 2013) · Net revenues were SEK 5,335,000 (0) and other operating income was SEK 159,000 (310,000). · Loss before tax was SEK -1,467,000 (-4,056,000). · Earnings per